The Janssen Pharmaceutical Companies of
These updated data from the ALCYONE study also demonstrated that the addition of DARZALEX to VMP resulted in higher rates of minimal residual disease (MRD) negativity.1 These data are the first OS results from the ALCYONE study and are being featured during an oral session at the 2019
'As a physician treating patients with multiple myeloma, I want to achieve the deepest response in the frontline setting to hopefully provide long-term benefit,' said
Results of a prespecified interim analysis, after a median duration of follow-up of more than three years, showed an estimated 42-month OS rate of 75 percent for DARZALEX-VMP versus 62 percent for VMP, with a statistically significant improvement in OS observed for DARZALEX-VMP versus VMP alone (hazard ratio [HR]=0.60; 95 percent confidence interval [CI], 0.46-0.80; P=0.0003).1 Of note, median OS was not assessed in either group and follow-up is ongoing. In addition, DARZALEX-VMP resulted in a median progression-free survival (PFS) of 36.4 months versus 19.3 months with VMP alone after a median follow-up of 40.1 months (HR=0.42; 95 percent CI, 0.34-0.51; P
(C) 2019 Electronic News Publishing, source